Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 168

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors

Open access
Goethals, Olivia, Clayton, Reginald, Van Ginderen, Marcia, Vereycken, Inge, Wagemans, Elisabeth, Geluykens, Peggy, Dockx, Koen, Strijbos, Rudy, Smits, Veerle, Vos, Ann, Meersseman, Geert, Jochmans, Dirk, Vermeire, Kurt, Schols, Dominique, Hallenberger, Sabine, Hertogs, Kurt·2008·Journal of Virology

Abstract

Integration of viral DNA into the host chromosome is an essential step in the life cycle of retroviruses and is facilitated by the viral integrase enzyme. The first generation of integrase inhibitors recently approved or currently in late-stage clinical trials shows great promise for the treatment of human immunodeficiency virus (HIV) infection, but virus is expected to develop resistance to these drugs. Therefore, we used a novel resistance selection protocol to follow the emergence of resistant HIV in the presence of the integrase inhibitor elvitegravir (GS-9137). We find the primary resistance-conferring mutations to be Q148R, E92Q, and T66I and demonstrate that they confer a reduction in susceptibility not only to elvitegravir but also to raltegravir (MK-0518) and other integrase inhibitors. The locations of the mutations are highlighted in the catalytic sites of integrase, and we correlate the mutations with expected drug-protein contacts. In addition, mutations that do not confer reduced susceptibility when present alone (H114Y, L74M, R20K, A128T, E138K, and S230R) are also discussed in relation to their position in the catalytic core domain and their proximity to known structural features of integrase. These data broaden the understanding of antiviral resistance against integrase inhibitors and may give insight facilitating the discovery of second-generation compounds.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/jvi.00470-08

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 168

Metadata

Authors
Goethals, O., Clayton, R., Van Ginderen, M., Vereycken, I., Wagemans, E., Geluykens, P., Dockx, K., Strijbos, R., Smits, V., Vos, A., Meersseman, G., Jochmans, D., Vermeire, K., Schols, D., Hallenberger, S., & Hertogs, K.
Venue
Journal of Virology
Published
2008-11
Volume
82
Issue
21
Pages
10366-10374
ISSN
  • 0022-538X (ISSN-L)
  • 1098-5514
OpenAlex
W2139876724
Cited by
168
References
5
FWCI
12.03
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors. https://app.cochat.ai/papers/10.1128/jvi.00470-08
The paper
Goethals, O., Clayton, R., Van Ginderen, M., Vereycken, I., Wagemans, E., Geluykens, P., Dockx, K., Strijbos, R., Smits, V., Vos, A., Meersseman, G., Jochmans, D., Vermeire, K., Schols, D., Hallenberger, S., & Hertogs, K. (2008). Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors. Journal of Virology. https://doi.org/10.1128/jvi.00470-08

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.